Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study

Helena Marzo-Ortega,J. Sieper,Alan J. Kivitz,Ricardo Blanco,Martin Cohen,R. Martin,A. Readie,H. Richards,B. Porter
DOI: https://doi.org/10.1002/acr.23233
2017-06-07
Arthritis Care & Research
Abstract:Secukinumab improved the signs and symptoms of ankylosing spondylitis (AS) over 52 weeks in the phase III MEASURE 2 study. Here, we report longer‐term (104 weeks) efficacy and safety results.
What problem does this paper attempt to address?